July 20, 2026•1 min read•from TechCrunch

Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation

The de-extinction startup is looking to double or triple its previous valuation, according to the report.

Check out the full article on the original site

#de-extinction

#valuation

#Colossal Biosciences

#startup

#capital

#funding

#investment

#private equity

#biotechnology

#venture capital

#genetics

#conservation

#species revival

#mammoth

#woolly mammoth

#genome editing

#CRISPR

#resurrection